Logo Image
|Articles|August 7, 2007

Quebec City in 1994, Montreal in 2001, and Toronto in 2007!

Quebec City in 1994, Montreal in 2001 and Toronto in 2007!

TORONTO, CANADA, July 26, 2007-Over the past fourteen years Anapharm has established itself as a world class provider of clinical and bioanalytical services to international sponsors and offers strategically located operations in five Canadian cities. Most recently, we opened a 160-bed clinical facility in Toronto, Canada.

Toronto site features:

  • Modern, efficient facilities;
  • Over 40,000 sq ft, on the 6th floor with ample natural light and park views;

  • Clinical site comprised of 4 spacious clinical units with a total capacity of 160 beds;
  • Units can be combined in order to conduct larger studies;
  • The clinic offers full clinical services and on-site Quality Assurance support. Project Management services continue to be offered at the same level of excellence as at our Quebec and Montreal sites. One of our bioanalytical sites is located nearby in Richmond Hill.

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more